Eisai Says FDA Wrongly Denied Drug Exclusivity Extension
Eisai Inc. told a Washington, D.C., federal judge Tuesday that the U.S. Food and Drug Administration should be required to extend market exclusivity periods for an epilepsy drug and a weight-loss...To view the full article, register now.
Already a subscriber? Click here to view full article